{
    "symbol": "PDSB",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-11 11:15:09",
    "content": " I think one of the things you'll probably realize compared to our peers is the quality of partners that we brought on to our programs, which we believe in addition to providing significant validation of the approach we've taken, as Matt also said, and as I said in the presentation is also very important in how we allocate our financial resources and the benefit that these partnerships have also provided to PDS in terms of our ability to broadly cover the HPV cancer space and actually perform for clinical trials with PDS0101 across all HPV cancer indications, right?"
}